Showing posts with label Mirabilis Medical. Show all posts
Showing posts with label Mirabilis Medical. Show all posts

Sunday, April 30, 2017

In case you missed it: Here are the top 5 posts this month.



Ethicon STRATAFIX™ Spiral Plus Devices transforms wound closure experience for surgeons.

Ethicon has launched Stratafix Spiral PDS Plus and Stratafix Spiral Monocryl Plus Knotless Tissue Control Devices that provides a unique edge over traditional suturing.
Stratafix sutures enables more strength, consistency, security and efficiency over its predecessors because the surgeon can manage tension and control tissue approximation with each pass. It also eliminates the need to tie knots.


Mayo Clinic Tampon Test for detecting Endometrial Cancer at early stage.

There is no standard screening test to identify endometrial cancer, hence it is often detected late when the disease has already advanced.
Mayo clinic expert Jamie N. Bakkum-Gamez, M.D. and her team are in the process of developing a simple screening test that can be done at home using a tampon. It is based on the concept of detecting tumor DNA hypermethylation in vaginal pool DNA picked up by ordinary tampon.

At last, a no surgery, no knife, noninvasive treatment for uterine fibroid receives European approval.

Mirabilis Medical, a Seattle based company received CE Mark authorization for marketing of the Mirabilis System for treatment of uterine fibroids throughout the European Union.  It also announced that it had received a green signal from US-FDA to begin its clinical studies in US.
The Mirabilis system is a High-Intensity Focused Ultrasound (HIFU) system consists of an ultrasound system that has two parts: the imaging part and the therapy part.

Synthetic progestogens, but not natural progesterone, lowers miscarriage risk among women with unexplained RPL: Systematic review and meta-analysis.

Women taking progestogens have a 28% lower risk of miscarriage (RR 0.72; 95% CI 0.53-0.97).  and 7% higher chances of live births as compared to women who did not receive any supplementation. (RR 1.07, 95% CI 1.02–1.15).
The Meta-analysis included 10 trials comprising a total of 1,586 women with history of recurrent miscarriage.

Sperms used as vehicle for targeted drug delivery in gynecological cancers.

Sperms are not just for baby-making anymore, but can be used as cargo agents for delivering drugs inside the body.
Getting the chemotherapeutic agent to only kill the tumor cells without affecting the normal cells is a dream come true in area of cancer therapeutics because of Targeted drug delivery systems(TDDS).
Targeted drug delivery systems using polymeric nanoparticles have opened up new avenues in cancer chemotherapy.  Liposomes have shown to be effective among an array of nano- and microcarriers but have the drawback of dilution by body fluids, decreased penetration and uptake by non-target tissues.


Saturday, April 8, 2017

Here are the top 5 posts this week.

 Mayo Clinic Tampon Test for detecting Endometrial Cancer at early stage
Mayo clinic expert Jamie N. Bakkum-Gamez, M.D. and her team are in the process of developing a simple screening test that can be done at home using a tampon. It is based on the concept of detecting tumor DNA hypermethylation in vaginal pool DNA picked up by ordinary tampon.

At last, a no surgery, no knife, noninvasive treatment for uterine fibroid receives European approval.
Mirabilis Medical, a Seattle based company received CE Mark authorization for marketing of the Mirabilis System for treatment of uterine fibroids throughout the European Union.  It also announced that it had received a green signal from US-FDA to begin its clinical studies in US.

Ethicon STRATAFIX™ Spiral Plus Devices transforms wound closure experience for surgeons.
It has launched Stratafix Spiral PDS Plus and Stratafix Spiral Monocryl Plus Knotless Tissue Control Devices that provides a unique edge over traditional suturing.

Test strips for point of care detection of cervical cancer: Reality in near future.
Researchers at Purdue are developing technology that could enable us to detect cervical cancer with low-cost, easy-to-use, lateral flow test strips that are very similar to home pregnancy tests.

ACOG updates guidelines on investigating microscopic hematuria in females.
The American College of Obstetricians and Gynecologists(ACOG)  and the American Urogynecologic Society (AUS) has updated its guidelines for low risk women presenting with microscopic hematuria.
The committee opinion was published online on March 30, 2017 ahead of print in Journal of Obstetrics and Gynecology.